221 related articles for article (PubMed ID: 26836763)
1. A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America.
Sarti E; L'Azou M; Mercado M; Kuri P; Siqueira JB; Solis E; Noriega F; Ochiai RL
Int J Infect Dis; 2016 Mar; 44():44-9. PubMed ID: 26836763
[TBL] [Abstract][Full Text] [Related]
2. Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America.
Dayan G; Arredondo JL; Carrasquilla G; Deseda CC; Dietze R; Luz K; Costa MSN; Cunha RV; Rey LC; Morales J; Reynales H; Miranda M; Zambrano B; Rivas E; Garbes P; Noriega F
Am J Trop Med Hyg; 2015 Jul; 93(1):18-23. PubMed ID: 26013373
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
L'Azou M; Moureau A; Sarti E; Nealon J; Zambrano B; Wartel TA; Villar L; Capeding MR; Ochiai RL; ;
N Engl J Med; 2016 Mar; 374(12):1155-66. PubMed ID: 27007959
[TBL] [Abstract][Full Text] [Related]
4. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
Gessner BD; Wilder-Smith A
Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
[TBL] [Abstract][Full Text] [Related]
5. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine.
Coudeville L; Baurin N; L'Azou M; Guy B
Vaccine; 2016 Dec; 34(50):6426-6435. PubMed ID: 27601343
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
[TBL] [Abstract][Full Text] [Related]
9. Dengue vaccine supplies under endemic and epidemic conditions in three dengue-endemic countries: Colombia, Thailand, and Vietnam.
Lee JS; Lim JK; Dang DA; Nguyen THA; Farlow A
Vaccine; 2017 Dec; 35(50):6957-6966. PubMed ID: 29110932
[TBL] [Abstract][Full Text] [Related]
10. Incidence rates of neurotropic-like and viscerotropic-like disease in three dengue-endemic countries: Mexico, Brazil, and Malaysia.
Cohen C; Moreira ED; Nañez H; Nachiappan JP; Arvinder-Singh HS; Huoi C; Nealon J; Sarti E; Puentes-Rosas E; Moureau A; Khromava A;
Vaccine; 2019 Mar; 37(13):1868-1875. PubMed ID: 30826144
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
[TBL] [Abstract][Full Text] [Related]
12. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
[TBL] [Abstract][Full Text] [Related]
13. Transmission thresholds for dengue in terms of Aedes aegypti pupae per person with discussion of their utility in source reduction efforts.
Focks DA; Brenner RJ; Hayes J; Daniels E
Am J Trop Med Hyg; 2000 Jan; 62(1):11-8. PubMed ID: 10761719
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A;
Lancet; 2014 Oct; 384(9951):1358-65. PubMed ID: 25018116
[TBL] [Abstract][Full Text] [Related]
16. Opportunities for improved surveillance and control of dengue from age-specific case data.
Rodriguez-Barraquer I; Salje H; Cummings DA
Elife; 2019 May; 8():. PubMed ID: 31120419
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of dengue and other arboviruses in a cohort of school children and their families in Yucatan, Mexico: Baseline and first year follow-up.
Rojas DP; Barrera-Fuentes GA; Pavia-Ruz N; Salgado-Rodriguez M; Che-Mendoza A; Manrique-Saide P; Vazquez-Prokopec GM; Halloran ME; Longini IM; Gomez-Dantes H
PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006847. PubMed ID: 30462635
[TBL] [Abstract][Full Text] [Related]
19. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
